Striverdi Respimat Patent Expiration

STRIVERDI RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(8 months ago)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(7 months ago)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(9 months from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7246615 BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generating device
May, 2016

(8 years ago)

US5964416 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6176442 BOEHRINGER INGELHEIM Device for mounting a component exposed to a pressurized fluid
Oct, 2016

(7 years ago)

US6726124 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US7104470 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6453795 BOEHRINGER INGELHEIM Locking mechanism for a spring-actuated device
Dec, 2016

(7 years ago)

US6149054 BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Dec, 2016

(7 years ago)

US6846413 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US6977042 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US7802568 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2019

(5 years ago)

US6988496 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2020

(4 years ago)

US7988001 BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Aug, 2021

(2 years ago)

US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(8 months ago)

US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(8 months ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(a month from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(9 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(10 months from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(2 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(2 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(3 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)



Striverdi Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is used for managing symptoms of chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema. Striverdi Respimat uses Olodaterol Hydrochloride as an active ingredient. Striverdi Respimat was launched by Boehringer Ingelheim in 2014. It is is available in spray, metered form for inhalation use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 16, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2018

Market Authorisation Date: 31 July, 2014

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED

More Information on Dosage

STRIVERDI RESPIMAT family patents

Family Patents